< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
1 - 10 of 110
- Angiogenesis and Vascular HeterogeneityFrom9 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Immunomodulatory role of graft endothelial cells to improve organ transplantationFrom30 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Demystifying the mystery genome for alternative immunotherapy targets: combining artificial intelligence-based discovery of immunomodulatory endothelial cell targets and in vivo target validation.From1 Oct 2022 → 30 Sep 2023Funding: BOF - postdoctoral mandates
- DEMYSTIFYING ALTERNATIVE IMMUNOTHERAPY MYSTERY TARGETS BY COMBINING ARTIFICIAL INTELLIGENCE- BASED TARGET DISCOVERY AND LARGER-SCALE TARGET VALIDATIONFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Immunomodulatory endothelial cells (IMECs): dissecting their immunosuppressive / im- munostimulatory features via nanoparticle-based gene silencing or overexpressionFrom26 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validating novel AI-predicted targets for alternative cancer immunotherapyFrom20 Sep 2022 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Angiogenesis and Vascular HeterogeneityFrom19 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metabolic and epigenetic interplay in neural progenitor cells: investigating neurodevelopmental disorders associated with impaired neural progenitor cell expansion (MEPIcephaly).From1 Jun 2022 → TodayFunding: FWO research project (including WEAVE projects)
- Imaging the invisible in preclinical models using magnetic particle imagingFrom1 May 2022 → TodayFunding: FWO Large scale research infrastructure
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
Publications
21 - 30 of 587
- HIF1A-dependent induction of alveolar epithelial PFKFB3 dampens acute lung injury(2022)
Authors: Peter Carmeliet
- Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells(2022)
Authors: Mieke Dewerchin, Peter Carmeliet
- CD8+ T cell metabolic rewiring defined by scRNA-seq identifies a critical role of ASNS expression dynamics in T cell differentiation(2022)
Authors: dorien Broekaert, Elodie Modave, Peter Carmeliet, Diether Lambrechts, Sarah-Maria Fendt
- Mitochondrial respiration supports autophagy to provide stress resistance during quiescence(2022)
Authors: Mieke Dewerchin, Peter Carmeliet
Pages: 2409 - 2426 - Metabolic Reprogramming in Tumor Endothelial Cells(2022)
Authors: Liliana Sokol, Peter Carmeliet
- Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast(2022)
Authors: Liliana Sokol, Maxim De Schepper, Edoardo Isnaldi, Anh-Co Truong, François Richard, Ann Smeets, Ines Nevelsteen, Birgit Weynand, Christine Desmedt, Patrick Neven, et al.
- A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma(2022)
Authors: Peter Carmeliet
Pages: 3950 - 3957 - Immunomodulation by endothelial cells - partnering up with the immune system?(2022)
Authors: Guy Eelen, Peter Carmeliet
Pages: 576 - 588 - Analyzing cell-type-specific dynamics of metabolism in kidney repair(2022)
Authors: Sébastien Dumas, Peter Carmeliet
Pages: 1109 - + - Tumor vessel co-option: The past & the future(2022)
Authors: Anh-Co Truong, Peter Carmeliet
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)